301 – 327 of 327
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- 4
- next »
- 1999
-
Mark
HELLP en livshotande graviditetskomplikation. Specifik koagulationsfaktorbehandling nu möjlig
(
- Contribution to journal › Article
-
Mark
Nytt system testar den mekaniska hjärtklaffen. Egenkontroll i hemmet av antivitamin K-terapin ger patienten större frihet
(
- Contribution to journal › Article
-
Mark
Centraliserad vård grundläggande i vårdprogram för blödarsjuka
(
- Contribution to journal › Article
-
Mark
Nya rön om behandling av djup ventrombos: Behandlingstidens längd föremål för internationella studier
(
- Contribution to journal › Article
-
Mark
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin
(
- Contribution to journal › Article
- 1998
-
Mark
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis
(
- Contribution to journal › Article
-
Mark
The Malmo-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
(
- Contribution to journal › Scientific review
-
Mark
Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum's disease: impact on haemostatic factors associated with cardiovascular disease and insulin sensitivity.
(
- Contribution to journal › Article
-
Mark
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation
(
- Contribution to journal › Article
-
Mark
Major surgery seems not to influence HIV disease progression in haemophilia patients
(
- Contribution to journal › Article
-
Mark
Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995
(
- Contribution to journal › Article
-
Mark
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B
(
- Contribution to journal › Article
- 1997
-
Mark
No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
(
- Contribution to journal › Article
-
Mark
Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study
(
- Contribution to journal › Article
-
Mark
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
(
- Contribution to journal › Article
-
Mark
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis
(
- Contribution to journal › Article
- 1996
-
Mark
Antitrombin III-koncentrat söker sin roll i terapin. Var försiktig och invänta studieresultat!
(
- Contribution to journal › Article
-
Mark
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
(
- Contribution to journal › Article
- 1995
-
Mark
Resistens mot aktiverat protein C. Vanlig genetisk riskfaktor för venös trombos
(
- Contribution to journal › Article
- 1994
-
Mark
Myocardial infarction associated with homozygous resistance to activated protein C
(
- Contribution to journal › Letter
-
Mark
Prophylactic treatment of severe hemophilia A and B can prevent joint disability
(
- Contribution to journal › Article
- 1992
-
Mark
Laparoscopic cholecystectomy in a patient with hemophilia B
(
- Contribution to journal › Article
-
Mark
Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia
(
- Contribution to journal › Article
- 1991
-
Mark
Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B
(
- Contribution to journal › Article
- 1990
-
Mark
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate
(
- Contribution to journal › Letter
-
Mark
Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate
(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- 4
- next »